This is a historical report — it no longer reflects this drug's current status. Current status: Active Shortage. View this drug's full profile page →

Anticipated Shortage

APO-DABIGATRAN

APOTEX INC

View this drug's full profile page →

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of APO-DABIGATRAN in Canada?

Yes. APO-DABIGATRAN 150MG has an active shortage reported to Health Canada (last updated October 24, 2024).

Why is APO-DABIGATRAN not available?

The reason the manufacturer reported: Disruption of the manufacture of the drug.

When will APO-DABIGATRAN be available again?

No estimated resolution date has been reported yet. Follow this page to get an email as soon as the status changes.

Can I still get this?Possibly — same-ingredient product records found

StatusAnticipated Shortage

Same-ingredient products on file2 products

Expected resolution~25 days remaining (estimate)

Affected strength150MG

Last updated2026-09-01

Other Products Containing the Same Active Ingredient

These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.

Other Products

TEVA-DABIGATRAN

TEVA CANADA LIMITED

75MG · DIN 02463458

Different strengthSame dosage formSame routeNo current shortage

Compare these two →

APO-DABIGATRAN

APOTEX INC

75MG · DIN 02468891

Different strengthSame dosage formSame routeNo current shortage

Compare these two →

What this means

Does this mean my pharmacy is already out of stock?

No — this shortage hasn't started yet. It's an early warning that supply may become tight, based on information from the manufacturer.

What should I do?

No action is needed yet. It's worth asking your pharmacist at your next refill whether they expect any disruption for this product.

Estimated Resolution

2026-10-23

~25 days remaining (estimate)

This is the manufacturer's estimated date, not a guarantee — actual resolution may come earlier or later.

DIN

02468913

Strength

150MG

Dosage Form

CAPSULE

Route

ORAL

Active Ingredient

DABIGATRAN ETEXILATE

Tier

Unrated

Last Updated

2026-09-01

Reason for Shortage

Disruption of the manufacture of the drug.

Source

View original report on healthproductshortages.ca ↗

Past Reports for This Drug

APO-DABIGATRAN has 2 shortage/discontinuation reports on file — this is one of them.

2024-10-24

Active Shortage

Disruption of the manufacture of the drug.

Other Products from APOTEX INC

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

24HR NASAL ALLERGY RELIEF

50MCG · DIN 02460513

ACETAMINOPHEN CAPLETS 325 MG

325MG · DIN 02362341

ACETAMINOPHEN CAPLETS 500 MG

500MG · DIN 02362368

ACETAMINOPHEN HEADACHE ULTRA RELIEF

DIN 02290901

ACETAMINOPHEN TABLETS USP 325 MG

325MG · DIN 02362422

ACETAMINOPHEN TABLETS USP 500 MG

500MG · DIN 02362244